Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
CARGO Therapeutics, Inc. (CRGX)
NASDAQ:CRGX
RESEARCH TOOLSreports
CRGX Stock Chart & Stats
Day’s Range― - ―
52-Week Range$3.00 - $33.92
Previous CloseN/A
Volume19.28K
Average Volume (3M)1.53M
Market Cap
$170.30M
Enterprise Value$503.14M
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta2.81
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.55
Shares Outstanding46,027,725
10 Day Avg. Volume825,304
30 Day Avg. Volume1,531,470
Standard Deviation0.27
R-Squared0.05
Alpha-0.09
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)294.64
Price to Cash Flow (P/CF)-1.10
P/FCF Ratio0.00
Enterprise Value/Market Cap2.95
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-136.28
Enterprise Value/Ebitda-3.24
Forecast
1Y Price Target
$4.50Price Target Upside21.95% Upside
Rating ConsensusHold
Number of Analyst Covering9
---
Bulls Say, Bears Say
Bulls Say
Financial StrategyA workforce reduction of approximately 50% is being implemented by Cargo Therapeutics to preserve cash, which may enhance financial stability.
Product DevelopmentCargo Therapeutics is advancing its tri-specific CAR-T candidate, CRG-023, into a Phase 1 dose escalation study, which indicates continued innovation in their product pipeline.
Regulatory ProgressCargo Therapeutics has a cleared IND for CRG-023, allowing them to move forward with a Phase 1 open-label dose escalation and expansion study to evaluate safety and activity.
Bears Say
Clinical TrialsCRGX is discontinuing the Phase II study of its lead asset firi-cel due to safety concerns and weak durability of efficacy, leading to a major setback in their clinical pipeline.
Market PerceptionThe stock is expected to trade sideways due to the perceived platform risks and recent discontinuation of the FIRCE-1 trial.
Safety ConcernsSafety data indicated that 18% of patients developed grade 3-5 immune effector cell-associated hemophagocytic lymphohistiocytosis-like syndrome, which raises significant safety concerns for CRGX's treatments.
---
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
CRGX FAQ
What was CARGO Therapeutics, Inc.’s price range in the past 12 months?
CARGO Therapeutics, Inc. lowest stock price was $3.00 and its highest was $33.92 in the past 12 months.
What is CARGO Therapeutics, Inc.’s market cap?
CARGO Therapeutics, Inc.’s market cap is $170.30M.
When is CARGO Therapeutics, Inc.’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were CARGO Therapeutics, Inc.’s earnings last quarter?
CARGO Therapeutics, Inc. released its earnings results on Aug 12, 2024. The company reported -$1.02 earnings per share for the quarter, missing the consensus estimate of -$1.004 by -$0.016.
Is CARGO Therapeutics, Inc. overvalued?
According to Wall Street analysts CARGO Therapeutics, Inc.’s price is currently Undervalued.
Does CARGO Therapeutics, Inc. pay dividends?
CARGO Therapeutics, Inc. does not currently pay dividends.
What is CARGO Therapeutics, Inc.’s EPS estimate?
CARGO Therapeutics, Inc.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does CARGO Therapeutics, Inc. have?
CARGO Therapeutics, Inc. has 46,027,725 shares outstanding.
What happened to CARGO Therapeutics, Inc.’s price movement after its last earnings report?
CARGO Therapeutics, Inc. reported an EPS of -$1.02 in its last earnings report, missing expectations of -$1.004. Following the earnings report the stock price went down -9.981%.
Which hedge fund is a major shareholder of CARGO Therapeutics, Inc.?
Currently, no hedge funds are holding shares in CRGX
---
CARGO Therapeutics, Inc. Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$4.50 (21.95% Upside)
$4.50 (21.95% Upside)
Blogger Sentiment
Bullish
CRGX Sentiment 100%
Sector Average 70%
Sector Average 70%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-82.56%
12-Months-Change
Fundamentals
Return on Equity
-69.81%
Trailing 12-Months
Asset Growth
447.20%
Trailing 12-Months
Company Description
CARGO Therapeutics, Inc.
CARGO Therapeutics, Inc., a clinical-stage biotechnology company, develops chimeric antigen receptor (CAR) T-cell therapies for cancer patients. The company's lead program is CRG-022, an autologous CD22 CAR T-cell product candidate designed to address resistance mechanisms by targeting CD22, an alternate tumor antigen that is expressed in B-cell malignancies. It also develops CRG-023, a tri-specific CAR T product candidate that targets tumor cells with three B-cell antigen targets. The company was formerly known as Syncopation Life Sciences, Inc. and changed its name to CARGO Therapeutics, Inc. in September 2022. CARGO Therapeutics, Inc. was incorporated in 2019 and is headquartered in San Mateo, California.
---
CRGX Stock 12 Month Forecast
Average Price Target
$4.50
▲(21.95% Upside)
Technical Analysis
Bluebird Bio
―
Fate Therapeutics
―
Iovance Biotherapeutics
―
Adaptimmune Therapeutics
―
Best Analysts Covering CRGX
1 Year
1 Year Success Rate
1/5 ratings generated profit
1 Year Average Return
-48.70%
downgraded a sell rating 23 days ago
Copying Brian Cheng's trades and holding each position for 1 Year would result in 20.00% of your transactions generating a profit, with an average return of -48.70% per trade.
---